Identification
- Summary
Clidinium is a synthetic anticholinergic used to treat peptic ulcer disease, colicky abdominal pain, diverticulitis, and IBS.
- Brand Names
- Chlorax, Librax
- Generic Name
- Clidinium
- DrugBank Accession Number
- DB00771
- Background
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Clidinium (DB00771)
- Weight
- Average: 352.4467
Monoisotopic: 352.191268703 - Chemical Formula
- C22H26NO3
- Synonyms
- 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
- 3-hydroxy-1-methylquinuclidinium benzilate ester
- Bromure de Clidinium
- Bromuro de clidinio
- Clidinii Bromidum
- Clidinium bromid
- N-methyl quinuclidinyl benzilate
Pharmacology
- Indication
For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. In combination with chlordiazepoxide, clidinium is indicated to control emotional and somatic factors in gastrointestinal disorders, and is used as adjunctive therapy in the treatment of peptic ulcer, irritable bowel syndrome and acute enterocolitis.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used as adjunct in combination to treat Irritable bowel syndrome Combination Product in combination with: Chlordiazepoxide (DB00475) •••••••••••• Used as adjunct in combination to treat Peptic ulcer disease Combination Product in combination with: Chlordiazepoxide (DB00475) •••••••••••• Used as adjunct in combination to treat Acute enterocolitis Combination Product in combination with: Chlordiazepoxide (DB00475) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
- Mechanism of action
Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.
Target Actions Organism AMuscarinic acetylcholine receptor M1 antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Clidinium is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Clidinium is combined with Acetazolamide. Acetophenazine The risk or severity of CNS depression can be increased when Clidinium is combined with Acetophenazine. Aclidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Clidinium. - Food Interactions
- Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of the combination product Chlordiazepoxide HCl and Clidinium Bromide.
- Take before a meal.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Clidinium Bromide 91ZQW5JF1Z 3485-62-9 GKEGFOKQMZHVOW-UHFFFAOYSA-M - Product Images
- International/Other Brands
- Dolibrax (Roche) / Porsucon (Ying Yuan) / Quarzan (Roche) / Sedaspa (Hua Shin)
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AA PHARMA CHLORAX CAPSULE Clidinium Bromide (2.5 mg) + Chlordiazepoxide hydrochloride (5 mg) Capsule Oral PHARMAFORTE SINGAPORE PTE LTD 1989-07-06 Not applicable Singapore 
CHLOBAX TABLET Clidinium Bromide (2.5 mg) + Chlordiazepoxide (5 mg) Tablet, sugar coated Oral BEACONS PHARMACEUTICALS PTE. LTD. 1996-04-19 Not applicable Singapore Chlorax Clidinium Bromide (2.5 mg) + Chlordiazepoxide hydrochloride (5 mg) Capsule Oral Aa Pharma Inc 1984-12-31 Not applicable Canada 
Chlordiazepoxide HCl and Clidinium Bromide Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral Micro Labs Limited 2022-10-01 Not applicable US 
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral Ascend Laboratories, LLC 2021-04-27 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Chlordiazepoxide Clidinium Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral River's Edge Pharmaceuticals, LLC 2009-06-02 2012-03-31 US CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral Golden State Medical Supply 2010-01-22 2012-03-30 US Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral Physicians Total Care, Inc. 1996-06-20 2013-01-15 US Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral ECI Pharmaceuticals, LLC 2011-05-04 Not applicable US Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1) Capsule Oral Breckenridge Pharmaceutical, Inc. 2009-02-01 2011-02-28 US
Categories
- ATC Codes
- A03CA02 — Clidinium and psycholeptics
- Drug Categories
- Acids, Carbocyclic
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Anticholinergic Agents
- Autonomic Agents
- Benzilates
- Central Nervous System Depressants
- Decreased Parasympathetic Acetylcholine Activity
- Digestive/GI System Activity Alteration
- Diphenylacetic Acids
- Drugs for Functional Gastrointestinal Disorders
- GI Motility Alteration
- Hydroxy Acids
- Muscarinic Antagonists
- Parasympatholytics
- Peripheral Nervous System Agents
- Phenylacetates
- Quinuclidines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Quinuclidines / Piperidines / Tetraalkylammonium salts / Tertiary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides show 5 more
- Substituents
- Alcohol / Amine / Aromatic alcohol / Aromatic heteropolycyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diphenylmethane / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- carboxylic ester, organic cation, quaternary ammonium ion (CHEBI:3743)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- BO76JF850N
- CAS number
- 7020-55-5
- InChI Key
- HOOSGZJRQIVJSZ-NNBUQUNQSA-N
- InChI
- InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+
- IUPAC Name
- (1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium
- SMILES
- C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
References
- Synthesis Reference
Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
- General References
- FDA Approved Drug Products: Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsules for oral use [Link]
- External Links
- Human Metabolome Database
- HMDB0014909
- KEGG Compound
- C07853
- PubChem Compound
- 2784
- PubChem Substance
- 46507814
- ChemSpider
- 26330531
- BindingDB
- 50055977
- 21232
- ChEBI
- 3743
- Therapeutic Targets Database
- DAP001117
- PharmGKB
- PA164781044
- Guide to Pharmacology
- GtP Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Clidinium_bromide
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count Not Available Unknown Status Treatment Chest Pain 1
Pharmacoeconomics
- Manufacturers
- Hoffmann la roche inc
- Packagers
- Avkare Incorporated
- Boca Pharmacal
- Breckenridge Pharmaceuticals
- Bryant Ranch Prepack
- Comprehensive Consultant Services Inc.
- Corepharma LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Excellium Pharmaceutical Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- KVK-Tech Inc.
- Legacy Pharmaceuticals Packaging LLC
- Macoven Pharmaceuticals LLC
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- Nucare Pharmaceuticals Inc.
- Oceanside Pharmaceuticals Incorporated
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Provident Pharmaceuticals LLC
- Resource Optimization and Innovation LLC
- River's Edge Pharmaceuticals
- Southwood Pharmaceuticals
- Veratex Corp.
- Dosage Forms
Form Route Strength Tablet, sugar coated Oral 5 mg Capsule Oral Capsule, gelatin coated Oral Tablet, film coated Oral Pill Oral Tablet, coated Oral Tablet, sugar coated Oral Tablet, film coated Oral - Prices
Unit description Cost Unit Quarzan 5 mg capsule 0.3USD capsule Quarzan 2.5 mg capsule 0.23USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 240-241 °C Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc. - Predicted Properties
Property Value Source Water Solubility 0.000377 mg/mL ALOGPS logP -0.5 ALOGPS logP -1.1 Chemaxon logS -6 ALOGPS pKa (Strongest Acidic) 11.05 Chemaxon pKa (Strongest Basic) -4.5 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 46.53 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 112.14 m3·mol-1 Chemaxon Polarizability 38.79 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9243 Blood Brain Barrier + 0.9142 Caco-2 permeable + 0.671 P-glycoprotein substrate Substrate 0.8526 P-glycoprotein inhibitor I Non-inhibitor 0.7661 P-glycoprotein inhibitor II Non-inhibitor 0.9576 Renal organic cation transporter Inhibitor 0.6314 CYP450 2C9 substrate Non-substrate 0.7781 CYP450 2D6 substrate Non-substrate 0.6956 CYP450 3A4 substrate Substrate 0.6095 CYP450 1A2 substrate Non-inhibitor 0.9528 CYP450 2C9 inhibitor Non-inhibitor 0.9459 CYP450 2D6 inhibitor Inhibitor 0.6154 CYP450 2C19 inhibitor Non-inhibitor 0.9577 CYP450 3A4 inhibitor Non-inhibitor 0.9504 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9889 Ames test Non AMES toxic 0.8557 Carcinogenicity Non-carcinogens 0.933 Biodegradation Ready biodegradable 0.7763 Rat acute toxicity 2.4948 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8162 hERG inhibition (predictor II) Non-inhibitor 0.6539
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-053r-1900000000-8a939c4028b1d50eacc4 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 180.52504 predictedDeepCCS 1.0 (2019) [M+H]+ 182.92061 predictedDeepCCS 1.0 (2019) [M+Na]+ 189.12715 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at December 02, 2023 06:59